Algeria's Ministry of Pharmaceutical Industry addresses Levothyrox shortage concerns, promises supply normalization

Algeria's Ministry of Pharmaceutical Industry has responded to growing concerns from thyroid patients regarding a shortage of Levothyrox, assuring that supplies will return to normal next week. The ministry officially addressed the alert raised by Dr. Abderrahim Bounekta, who highlighted in a widely shared video the significant difficulties patients faced in obtaining this vital treatment, citing disruptions over nearly six months. The ministry confirmed it is closely monitoring the situation and has conducted a thorough inventory of available stocks. According to ministerial services, the medication will be available in sufficient quantities and all dosages starting early next week. Control brigades remain mobilized to monitor the distribution chain and rectify any dysfunctions across the country's wilayas. In a long-term strategy to end cyclical crises, the ministry announced the launch of local production of an Algerian version of Levothyrox, scheduled to begin in January 2027, aiming for stable supply and reduced import dependence. Dr. Bounekta, while commending the authorities' responsiveness, urged pharmacists to strictly dispense the medication only with a prescription and advised patients to avoid excessive precautionary purchases, which exacerbate shortages and deprive others of their treatment. This joint effort by health professionals and public authorities aims to alleviate fears of a complete shortage of this essential medication for thousands of Algerians.